We describe the development of α-LGR5 as a therapeutic antibody, and its functional validation in targeting LGR5+ CRC and pre-B-ALL cells as an ADC and by directing cytotoxic immune cancer cell killing in the BiTE and CAR modalities. Here, LGR5 is linked to cancer.